Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells
| dc.contributor.author | Bulut G. | |
| dc.contributor.author | Atmaca H. | |
| dc.contributor.author | Karaca B. | |
| dc.date.accessioned | 2025-04-10T11:07:25Z | |
| dc.date.available | 2025-04-10T11:07:25Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Aim: AT-101 is a polyphenolic compound with potent anti-apoptotic effects in various cancers. In this study, the possible synergistic cytotoxic and apoptotic effect of trastuzumab/AT-101 combination was investigated in HER2-positive breast cancer cell lines. Materials & methods: SKBR-3, MDA-MB-453 and MCF-10A cell lines were treated with a trastuzumab/AT-101 combination. Synergistic cytotoxicity and apoptosis effects were shown and then PI3K and Akt protein levels were studied. Result: The trastuzumab/AT-101 combination induced synergistic cytotoxicity and apoptosis in both breast cancer cells but not in MCF-10A cells. Combination treatment induced cytotoxicity via inhibiting PI3K/AKT but not the MAPK/ERK pathway. Conclusion: The trastuzumab/AT-101 combination may be a good candidate for patients with trastuzumab-resistant Her2-positive breast cancer and inhibition of the PI3K/AKT pathway may be one of the underlying mechanisms. © 2019 Gulcan Bulut, Harika Atmaca & Burcak Karaca. | |
| dc.identifier.DOI-ID | 10.2217/fon-2019-0521 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/47371 | |
| dc.publisher | Future Medicine Ltd. | |
| dc.title | Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells | |
| dc.type | Article |